Cmon, forget about investor conference call, we need answers on the changes in the dividend listings (the second listing has been decoded to a 0 value) and the first dividend continues trading "nugx" and after an initial spike is far far below the projected "ngio" offering price. No official statement has been given on these developments.
Perhaps, this would have all been handled better if.parent holding company gnbt had some actual employees rather than outsourcing on securities regulations compliance and actual employees on medical research and development regulatory compliance. It seems as if they are shooting from the hip.
Generex Biotechnology Corp. (GNBT) Stock Research Links